Capricor Therapeutics (CAPR) Return on Sales (2016 - 2025)
Historic Return on Sales for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to 1.99%.
- Capricor Therapeutics' Return on Sales rose 35600.0% to 1.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.99%, marking a year-over-year decrease of 7900.0%. This contributed to the annual value of 1.01% for FY2024, which is 1200.0% down from last year.
- Latest data reveals that Capricor Therapeutics reported Return on Sales of 1.99% as of Q3 2025, which was up 35600.0% from 1.46% recorded in Q2 2025.
- Over the past 5 years, Capricor Therapeutics' Return on Sales peaked at 0.07% during Q4 2023, and registered a low of 126.22% during Q1 2021.
- In the last 5 years, Capricor Therapeutics' Return on Sales had a median value of 2.69% in 2023 and averaged 22.59%.
- Within the past 5 years, the most significant YoY rise in Capricor Therapeutics' Return on Sales was 1701200bps (2021), while the steepest drop was -1150000bps (2021).
- Over the past 5 years, Capricor Therapeutics' Return on Sales (Quarter) stood at 85.26% in 2021, then soared by 91bps to 8.01% in 2022, then skyrocketed by 99bps to 0.07% in 2023, then plummeted by -254bps to 0.24% in 2024, then tumbled by -720bps to 1.99% in 2025.
- Its Return on Sales stands at 1.99% for Q3 2025, versus 1.46% for Q2 2025 and 0.87% for Q1 2025.